Fierce Biotech Names Amylyx Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2020
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating Amylyx as one of the most promising private biotechnology companies in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005617/en/
The 2020 Fierce 15 comes at a time when the world is focused on a pandemic, but even as coronavirus remains a threat, patients with cancer, rare diseases and other disorders still need treatment, Fierce Biotech Senior Editor Ben Adams said. “This year, we’ve chosen from a diverse range of those fighting COVID, as well as those fighting longer term plagues against our biology,” Adams said.
Amylyx’ lead product candidate, AMX0035, is an investigational neuroprotective therapy that seeks to prevent or reduce neuron death and